Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 76

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Small cell lung cancer+1

Not recruiting

Study of Atezolizumab, Carboplatin, and Etoposide with or Without Tiragolumab for Patients with Untreated Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer recurrent+1

Not recruiting

Study of CLN-081 tablets in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations who have previously received platinum chemotherapy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cln-081
  • Sponsor:Cullinan Pearl Corp.

Obstructive sleep apnoea syndrome

Not recruiting

Study of sulthiame combined with oral appliance therapy for patients with obstructive sleep apnea who have incomplete response to oral appliance treatment alone

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sultiame
  • Sponsor:Vaestra Goetalandsregionen

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Investigational
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dexpramipexole Dihydrochloride Monohydrate
  • Sponsor:Areteia Therapeutics Inc.

Pulmonary arterial hypertension

Not recruiting

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Pulmonary arterial hypertension

Not recruiting

Long-term Study of Sotatercept for Adults with Pulmonary Arterial Hypertension (PAH)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Pleural mesothelioma malignant recurrent

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Malignant Pleural Mesothelioma in Second and Third Line Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Non-small cell lung cancer

Not recruiting

Study on the Effectiveness and Safety of Osimertinib for Patients with Early-Stage Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study on Ceralasertib, Oleclumab, and Monalizumab for Advanced Non-Small Cell Lung Cancer Patients Resistant to PD-1 Inhibitors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:Centre Hospitalier Regional De Marseille

Non-small cell lung cancer

Not recruiting

Study Comparing Cemiplimab to Platinum-Based Chemotherapy for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Non-small cell lung cancer

Not recruiting

Study of Cemiplimab and Chemotherapy Combination for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

COVID-19

Not recruiting

Study of Baricitinib in Children Aged 1 to 17 Hospitalized with COVID-19

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.